Efficacy profiles for different concentrations of Lactobacillus acidophilus in experimental colitis

被引:18
作者
Chen, Lin-Lin [1 ]
Zou, Yi-You [1 ]
Lu, Fang-Gen [2 ]
Li, Fu-Jun [1 ]
Lian, Guang-Hui [1 ]
机构
[1] Cent South Univ, Xiangya Hosp, Dept Gastroenterol, Changsha 410008, Hunan, Peoples R China
[2] Cent South Univ, Xiangya Hosp 2, Dept Gastroenterol, Changsha 410011, Hunan, Peoples R China
关键词
Lactobacillus acidophilus; Bifidobacterium; Colonic flora; Therapeutic dose; Experimental colitis; Efficacy profile; VSLNUMBER-3; PROBIOTIC-MIXTURE; INFLAMMATORY-BOWEL-DISEASE; ULCERATIVE-COLITIS; BIFIDOBACTERIUM; PATHOGENESIS; REMISSION; BACTERIAL; THERAPY; CASEI; GUT;
D O I
10.3748/wjg.v19.i32.5347
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
AIM: To determine the efficacy profiles of different concentrations of Lactobacillus acidophilus (L. acidophilus) for treating colitis using an experimental murine model. METHODS: Colitis was established in 64 BALB/c mice by adding 5% dextran sodium sulfate (DSS) to the drinking water and allowing ad libitum access for 7 d. The mice were then randomly divided into the following control and experimental model groups (n = 8 each; day 0): untreated model control; negative-treatment model control (administered gavage of 1 mL/10 g normal saline); experimental-treatment models C4-C8 (administered gavage of 10(4), 10(5), 10(6), 10(7), or 10(8) CFU/10 g L. acidophilus, respectively); positive-treatment model control (administration of the anti-inflammatory agent prednisone acetate at 45 mu g/10 g). Eight mice given regular water (no DSS) and no subsequent treatments served as the normal control group. Body weight, fecal traits, and presence of fecal occult blood were assessed daily. All animals were sacrificed on post-treatment day 7 to measure colonic length, perform histological scoring, and quantify the major bacteria in the proximal and distal colon. Intergroup differences were determined by one-way ANOVA and post-hoc Student-Newman-Keuls comparison. RESULTS: All treatments (L. acidophilus and prednisone acetate) protected against colitis-induced weight loss (P < 0.05 vs model and normal control groups). The extent of colitis-induced colonic shortening was significantly reduced by all treatments (prednisone acetate > C4 > C5 > C7 > C8 > C6; P < 0.05 vs untreated model group), and the C6 group showed colonic length similar to that of the normal control group (P > 0.05). The C6 group also had the lowest disease activity index scores among the model groups. The bacterial profiles in the proximal colon were similar between all of the experimental-treatment model groups (all P > 0.05). In contrast, the bacterial profile in the distal colon of the C6 group showed the distinctive features (P < 0.05 vs all other experimental-treatment model groups) of Lactobacillus sp. and Bifidobacterium sp. being the most abundant bacteria and Staphylococcus aureus being the least abundant bacteria. CONCLUSION: The most therapeutically efficacious concentration of L. acidophilus (106 CFU/10 g) may exert its effects by modulating the bacterial profile in the distal colon. c 2013 Baishideng. All rights reserved.
引用
收藏
页码:5347 / 5356
页数:10
相关论文
共 35 条
[11]  
Hamamoto N, 1999, CLIN EXP IMMUNOL, V117, P462
[12]   Anti-inflammatory activity of probiotic Bifidobacterium:: Enhancement of IL-10 production in peripheral blood mononuclear cells from ulcerative colitis patients and inhibition of IL-8 secretion in HT-29 cells [J].
Imaoka, Akemi ;
Shima, Tatsuichiro ;
Kato, Kimitoshi ;
Mizuno, Shigeaki ;
Uehara, Toshiki ;
Matsumoto, Satoshi ;
Setoyama, Hiromi ;
Hara, Taeko ;
Umesaki, Yoshinori .
WORLD JOURNAL OF GASTROENTEROLOGY, 2008, 14 (16) :2511-2516
[13]   Randomized controlled trial of the effect of bifidobacteria-fermented milk on ulcerative colitis [J].
Ishikawa, H ;
Akedo, I ;
Umesaki, Y ;
Tanaka, R ;
Imaoka, A ;
Otani, T .
JOURNAL OF THE AMERICAN COLLEGE OF NUTRITION, 2003, 22 (01) :56-63
[14]   Enteric Salmonella or Campylobacter infections and the risk of inflammatory bowel disease [J].
Jess, Tine ;
Simonsen, Jacob ;
Nielsen, Nete Munk ;
Jorgensen, Kristian Tore ;
Bager, Peter ;
Ethelberg, Steen ;
Frisch, Morten .
GUT, 2011, 60 (03) :318-324
[15]   Inflammatory Bowel Disease [J].
Kaser, Arthur ;
Zeissig, Sebastian ;
Blumberg, Richard S. .
ANNUAL REVIEW OF IMMUNOLOGY, VOL 28, 2010, 28 :573-621
[16]   Gut flora in health and disease [J].
Knight, DJW ;
Girling, KJ .
LANCET, 2003, 361 (9371) :1831-1831
[17]   Oral administration of probiotic bacteria (E-coli Nissle, E-coli O83, Lactobacillus casei) influences the severity of dextran sodium sulfate-induced colitis in BALB/c mice [J].
Kokesova, A. ;
Frolova, L. ;
Kverka, M. ;
Sokol, D. ;
Rossmann, P. ;
Bartova, J. ;
Tlaskalova-Hogenova, H. .
FOLIA MICROBIOLOGICA, 2006, 51 (05) :478-484
[18]   Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine [J].
Kruis, W ;
Fric, P ;
Pokrotnieks, J ;
Lukas, M ;
Fixa, B ;
Kascák, M ;
Kamm, MA ;
Weismueller, J ;
Beglinger, C ;
Stolte, M ;
Wolff, C ;
Schulze, J .
GUT, 2004, 53 (11) :1617-1623
[19]   Bacterial and fungal microbiota in relation to probiotic therapy (VSL#3) in pouchitis [J].
Kuehbacher, T. ;
Ott, S. J. ;
Helwig, U. ;
Mimura, T. ;
Rizzello, F. ;
Kleessen, B. ;
Gionchetti, P. ;
Blaut, M. ;
Campieri, M. ;
Foelsch, U. R. ;
Kamm, M. A. ;
Schreiber, S. .
GUT, 2006, 55 (06) :833-841
[20]   Prebiotics in Chronic Intestinal Inflammation [J].
Langen, Mirjam A. C. Looijer-Van ;
Dieleman, Levinus A. .
INFLAMMATORY BOWEL DISEASES, 2009, 15 (03) :454-462